Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.81 |
| ▸ | RAB9A | P51151 | 5/20 | 0.77 |
| ▸ | NPC1 | O15118 | 4/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.74 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167081 | 0.90 | NAMPT (1.00) | NAMPTRAB9ANPC1LMNAGAA | |
| Hydrochloric Acid SCHEMBL27890956 | 0.88 | NAMPT (0.97) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL5435462 | 0.87 | NAMPT (0.76) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL28007807 | 0.86 | NAMPT (0.81) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL95793 | 0.85 | NAMPT (0.73) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL6354168 | 0.85 | CYP11B1 (1.00) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL12078341 | 0.85 | NAMPT (0.77) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL30582756 | 0.85 | CYP11B1 (1.00) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL3403542 | 0.85 | NAMPT (0.73) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL5450085 | 0.85 | NAMPT (0.73) | NAMPTRAB9ANPC1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3049387-B1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & CO (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3049387-B1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & CO (US) | 2020-11-11 | — | — | EP | disclosed |
| US-9200142-B2 | Thermoplastic polymer composition | MILLIKEN & COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200144-B2 | Thermoplastic polymer composition | MILLIKEN & COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| US-9193845-B2 | Thermoplastic polymer composition | MILLIKEN & COMPANY (US) | 2015-11-24 | — | — | US | disclosed |
| US-9120914-B2 | Thermoplastic polymer composition | MILLIKEN & COMPANY (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150094406-A1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & COMPANY | 2015-04-02 | — | — | US | disclosed |
| WO-2015042565-A1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & COMPANY (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015042562-A1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & COMPANY (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20150087758-A1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & COMPANY | 2015-03-26 | — | — | US | disclosed |
| WO-2015042563-A1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & COMPANY (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015042561-A1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & COMPANY (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20150087759-A1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & COMPANY | 2015-03-26 | — | — | US | disclosed |
| US-20150087757-A1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & COMPANY | 2015-03-26 | — | — | US | disclosed |
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | disclosed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087757-A1 | THERMOPLASTIC POLYMER COMPOSITION | PARG, PUF60, MCM7 | NAMPT 1248/4885RAB9A 4453/4885NPC1 1837/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | NAMPT 2055/4885RAB9A 3569/4885NPC1 1069/4885 |
| US-20150087758-A1 | THERMOPLASTIC POLYMER COMPOSITION | ERCC4, SMCHD1, XRCC5 | NAMPT 861/4885RAB9A 4597/4885NPC1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.